<DOC>
	<DOCNO>NCT01481233</DOCNO>
	<brief_summary>The purpose study determine prostate specific antigen response continuous low dose oral colchicine .</brief_summary>
	<brief_title>Oral Colchicine Men With Castrate Resistant Prostate Cancer</brief_title>
	<detailed_description>The investigator propose simple phase II trial oral colchicine standard prophylactic dose utilized gout men CRPCa fail taxotere base chemotherapy . The investigator utilize simple modified Simon 2-stage design . The investigator plan enroll 40 men study . The men complete prior taxotere base therapy therapy post-taxotere include cabazitaxel one month prior receipt colchicine trial . Staging baseline bone scan , CT PSA well routine CBC , CMP PAP . The dose drug escalate tolerated maximum 1.2 mg bid . The patient would see 21 day interval . After every 3 cycle treatment , patient would restaged CT bone scan . Patients stable disease , partial response complete response would continue therapy either disease progression intolerable toxicity patient would take study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Castrate resistant prostate cancer Failure intolerance taxotere cabazitaxelbased chemotherapy abiraterone administer castrate resistant prostate cancer allow Age &gt; 18 year ability provide inform consent ECOG performance status 0 , 1 2 No prior use colchicine within last 2 year No chemotherapy , hormonal therapy , immunotherapy radiation therapy within 1 month day 1 , cycle 1 Inability provide inform consent Hypersensitivity colchicine Severe renal , gastrointestinal hepatic disorder Preexisting blood dyscrasia PLT &lt; 100K , ANC &lt; 1000 Serum Cr &gt; 2 x ULN Bilirubin &gt; 2 ULN AST &gt; 2 x ULN Concurrent use CYP3A4 inhibitor may increase drug level toxicity</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>oral colchicine</keyword>
	<keyword>castrate-resistant prostate cancer</keyword>
	<keyword>fail taxotere base chemotherapy</keyword>
</DOC>